• Rigel outlined strategy built around expanding commercial portfolio, maintaining financial discipline, pursuing in-licensing or M&A, and advancing development pipeline.
• Annual net product sales rose to $232 million in 2025 from $144.9 million in 2024; 2026 net product sales guidance set at $260 million.
• Q1 2026 net product sales totaled $54.9 million, up 26% versus Q1 2025; Tavalisse contributed $37.3 million, Gavreto $9.6 million, Rezlidhia $8 million.
• Company highlighted profitability since Q3 2024, citing more than $100 million increase in cash through end of 2025.
• Pipeline focus included advancement of R289 in lower-risk myelodysplastic syndrome alongside broader R289 portfolio opportunities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rigel Pharmaceuticals Inc. published the original content used to generate this news brief on May 05, 2026, and is solely responsible for the information contained therein.